Oncimmune is a pioneer, a leader
and an expert in early cancer
detection and improved cancer outcomes.
Since 2002, Oncimmune has pioneered technologies that enable early cancer detection. The company’s proprietary technology platform, EarlyCDT® is extensively validated for all types of lung cancer and for hepatocellular carcinoma (liver cancer). Oncimmune is helping to lead the advancement of early cancer detection across a range of solid tumour types.
Patented EarlyCDT®
autoantibody technology
Oncimmune‘s patented platform technology, EarlyCDT®, has been developed to detect multiple solid tumour types, making a universal test for these cancers theoretically possible. Currently, two products are available: EarlyCDT®—Lung and EarlyCDT®—Liver and more are in development.
EarlyCDT—Lung
Our autoantibody assay is optimised to help clinicians assess lung cancer probability in intermediate-risk lung nodules, with high accuracy. It is also being investigated as a screening test by the National Health Service (NHS) in Scotland, UK.
EarlyCDT—Liver
Our autoantibody assay can detect liver cancer (hepatocellular carcinoma) at all stages with similar performance for early- and late-stage disease
Learn more about our unique tests only available through Oncimmune®
EarlyCDT®―Lung
EarlyCDT®―Liver
Our Research & Development Partners
